
Sign up to save your podcasts
Or
In this podcast interview recorded at ASCO GU25, UROONCO bladder cancer chief editor Dr. Benjamin Pradere talked to Dr. Nadine Houede from CHU Nîmes, Hospital Caremeau in France, on the results of the iNDUCT trial.
The iNDUCT trial is a phase II trial evaluated safety and efficacy of neoadjuvant chemotherapy (cisplatin or carboplatin + gemcitabine) in combination with durvalumab in these patients. Dr. Houede discusses the rational, the results and next steps.
For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.
3.7
33 ratings
In this podcast interview recorded at ASCO GU25, UROONCO bladder cancer chief editor Dr. Benjamin Pradere talked to Dr. Nadine Houede from CHU Nîmes, Hospital Caremeau in France, on the results of the iNDUCT trial.
The iNDUCT trial is a phase II trial evaluated safety and efficacy of neoadjuvant chemotherapy (cisplatin or carboplatin + gemcitabine) in combination with durvalumab in these patients. Dr. Houede discusses the rational, the results and next steps.
For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.
785 Listeners
325 Listeners
22,074 Listeners
496 Listeners
135 Listeners
58 Listeners
183 Listeners
2 Listeners
3,685 Listeners
9 Listeners
56 Listeners
0 Listeners
1,625 Listeners
0 Listeners
2 Listeners